196 related articles for article (PubMed ID: 38323738)
21. Donanemab in early symptomatic Alzheimer's disease.
Drug Ther Bull; 2024 Apr; 62(5):67. PubMed ID: 38580400
[No Abstract] [Full Text] [Related]
22. Effect of Lecanemab in Early Alzheimer's Disease: Mechanistic Interpretation in the Amyloid Cascade Hypothesis 2.0 Perspective.
Volloch V; Rits-Volloch S
J Alzheimers Dis; 2023; 93(4):1277-1284. PubMed ID: 37212119
[TBL] [Abstract][Full Text] [Related]
23. Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies.
Digma LA; Winer JR; Greicius MD
J Alzheimers Dis; 2024; 97(2):567-572. PubMed ID: 38250779
[TBL] [Abstract][Full Text] [Related]
24. How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
Beveridge J; Kaniecki E; Naidu A; Silverglate BD; Grossberg G
Expert Opin Emerg Drugs; 2024 Mar; 29(1):35-43. PubMed ID: 38193477
[TBL] [Abstract][Full Text] [Related]
25. Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Qiao Y; Gu J; Yu M; Chi Y; Ma Y
CNS Drugs; 2024 Mar; 38(3):169-192. PubMed ID: 38429615
[TBL] [Abstract][Full Text] [Related]
26. Passive immunotherapy for Alzheimer's disease.
Guo X; Yan L; Zhang D; Zhao Y
Ageing Res Rev; 2024 Feb; 94():102192. PubMed ID: 38219962
[TBL] [Abstract][Full Text] [Related]
27. Once upon a time, the Amyloid Cascade Hypothesis.
Granzotto A; Sensi SL
Ageing Res Rev; 2024 Jan; 93():102161. PubMed ID: 38065226
[TBL] [Abstract][Full Text] [Related]
28. Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials.
Wolters FJ; Labrecque JA
Alzheimers Dement; 2024 Apr; 20(4):3119-3125. PubMed ID: 38380503
[TBL] [Abstract][Full Text] [Related]
29. Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.
Terao I; Kodama W
Ageing Res Rev; 2024 Feb; 94():102203. PubMed ID: 38253184
[TBL] [Abstract][Full Text] [Related]
30. Clinical and Scientific Challenges to Effectiveness Studies Under Coverage with Evidence Development in Alzheimer's Disease.
Morin PJ; Zhang Q; Xia W; Miller D; Querfurth H; Tahami Monfared AA
Neurol Ther; 2023 Jun; 12(3):721-726. PubMed ID: 36933140
[TBL] [Abstract][Full Text] [Related]
31. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ; Smith J; Donohue MC; Delmar P; Abbas R; Salloway S; Wojtowicz J; Blennow K; Bittner T; Black SE; Klein G; Boada M; Grimmer T; Tamaoka A; Perry RJ; Turner RS; Watson D; Woodward M; Thanasopoulou A; Lane C; Baudler M; Fox NC; Cummings JL; Fontoura P; Doody RS;
N Engl J Med; 2023 Nov; 389(20):1862-1876. PubMed ID: 37966285
[TBL] [Abstract][Full Text] [Related]
32. 'Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings.
Dickson SP; Wessels AM; Dowsett SA; Mallinckrodt C; Sparks JD; Chatterjee S; Hendrix S
J Prev Alzheimers Dis; 2023; 10(3):595-599. PubMed ID: 37357301
[TBL] [Abstract][Full Text] [Related]
33. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.
Hampel H; Elhage A; Cho M; Apostolova LG; Nicoll JAR; Atri A
Brain; 2023 Nov; 146(11):4414-4424. PubMed ID: 37280110
[TBL] [Abstract][Full Text] [Related]
34. Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit.
Høilund-Carlsen PF; Alavi A; Barrio JR; Castellani RJ; Costa T; Herrup K; Kepp KP; Neve RL; Perry G; Revheim ME; Robakis NK; Sensi SL; Vissel B
Ageing Res Rev; 2024 Jun; ():102348. PubMed ID: 38830549
[TBL] [Abstract][Full Text] [Related]
35. Profiling lecanemab as a treatment option for Alzheimer's disease.
Schiller ER; Silverglate BD; Grossberg GT
Expert Rev Neurother; 2024 May; 24(5):433-441. PubMed ID: 38566584
[TBL] [Abstract][Full Text] [Related]
36. Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease.
Cantillon M; Andreasen N; Prins N
J Prev Alzheimers Dis; 2024; 11(1):65-70. PubMed ID: 38230718
[TBL] [Abstract][Full Text] [Related]
37. Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Terao I; Kodama W
J Alzheimers Dis; 2024; 98(3):825-835. PubMed ID: 38461503
[TBL] [Abstract][Full Text] [Related]
38. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
39. APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials.
Evans CD; Sparks J; Andersen SW; Brooks DA; Hauck PM; Mintun MA; Sims JR
Alzheimers Dement; 2023 Dec; 19(12):5407-5417. PubMed ID: 37204338
[TBL] [Abstract][Full Text] [Related]
40. Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.
Lu D; Dou F; Gao J
Drug Discov Ther; 2023; 17(6):440-444. PubMed ID: 38220210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
